Impact BioMedical Inc (IBO) - Company Gross Revenue
Resilient demand for hygiene components protects Impact BioMedical Inc (IBO) from market volatility, a position reinforced by its ownership of unique patents in natural compounds targeting oncology and viruses. The company's sales time series visualizes this trend, where 0.00 defines the current value of the metric. A steady income stream is ensured by a royalty-based model from health product manufacturers.
Comprehensive metric breakdowns and analytics for Impact BioMedical (IBO)
- share price and expert price forecast:
- market capitalization indicators:
- book capitalization data:
- company liabilities and liquidity data:
Total Debt to Capital Impact BioMedical Inc|IBO - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Impact BioMedical, Inc.|IBO - Company Total Debt|Debt to Book Capital Impact BioMedical Inc|IBO - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Impact BioMedical|Quick Liquidity impactbiomedinc.com
- company profitability and valuation multiples indicators:
IBO - Net Profit|Company Profit Forecast Impact BioMedical Inc|IBO - Price to Earnings Ratio|Projected Price to Earnings Ratio impactbiomedinc.com|IBO - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Impact BioMedical Inc|IBO - Operating profit EBITDA|Net earnings per one share for the last twelve months Impact BioMedical|IBO - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last 12 months impactbiomedinc.com|IBO - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Impact BioMedical Inc
- sales volume and revenue indicators:
General company analysis:impactbiomedinc.com, IBO
This indicator accumulates daily cash inflows from product sales, allowing for the real-time tracking of operating income dynamics to identify plan deviations early. For Impact BioMedical Inc (IBO), the company's sales revenue reflects the effectiveness of monetizing intellectual property through license payments and royalties, confirming the market value of the holding's biomedical developments.
Competing companies
HLN: Company Sales Revenue|Revenue and Sales Volume KVUE|Company Gross Revenue veronapharma.com|Company Revenue Jyong Biotech MENS|LGND - Company Sales|AMRX - Company Revenue|Company Annual Revenue PRGO|ALVO: Revenue and Sales Volume|liquidia.com (LQDA) - Revenue and Sales Volume|GLPG (Galapagos) - Revenue and Sales Volume|Company Sales ANI Pharmaceuticals Inc (ANIP)|Company Sales MNKD (MannKind Corp.)|Company Total Sales AMPH|Pacira BioSciences - Company Sales|Company Sales Revenue SPRY|Theravance Biopharma, Inc. - Revenue and Sales Volume|AQST: Company Revenue|SCPH: Revenue and Sales Volume|TECX - Company Gross Revenue|Company Revenue Tonix Pharmaceuticals|Company Total Revenue SXT China SXTC|Company Revenue Eupraxia Pharmaceuticals (EPRX)|Company Sales BioHarvest Sciences, Inc. BHST|Revenue and Sales Volume EXOZ (Invizyne Technologies, Inc.)|Oramed (ORMP) - Company Total Revenue|Entera Bio Corp - Revenue and Sales Volume|HYFT (ipatherapeutics.com) - Company Sales Volume|ABVC: Revenue and Sales Volume|CPIX - Company Gross Revenue|QNTM (Quantum BioPharma Limited) - Revenue and Sales Volume|Company Sales FibroGen Corporation (FGEN)|Revenue and Sales Volume TELO|Revenue and Sales Volume ranitherapeutics.com (RANI)|Company Revenue Synergy CHC SNYR|Rallybio Corp - Company Revenue|LEXX: Company Sales|Company Sales Revenue PULM (Pulmatrix Corporation)|PTHL: Revenue and Sales Volume|APM - Company Gross Revenue|Company Revenue Lyra Therapeutics|Company Sales Volume TNFA (TNF Pharma)|Revenue and Sales Volume YCBD|Company Sales PainReform Corp PRFX|Revenue and Sales Volume CYTO (Altamira Therapeutics Ltd.)|Company Gross Revenue lipella.com (LIPO)|OptiNose - Revenue and Sales Volume|PIRS: Company Revenue|Procaps Group SA (PROC) - Company Revenue|Company Total Revenue Petros Pharma (PTPI)|Company Revenue Qilian International|acelyrin.com - Company Annual Revenue|Revenue and Sales Volume TFFP
